HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-05-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation if they have an HLA matched sibling, or an autologous transplant if they do not.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Grade Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

autologous and allogeneic stem cell transplantation low grade lymphoma mantle cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stem cell source

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* indolent histology lymphomas after relapse 1 or 2 LVEF \> 50% Creatinine \< 150 umol/L bilirubin \< 30 umol/L wbc \>3.5X10\^9/L platelets \>100X10\^9/L other medical condition as controlled

Exclusion Criteria

* pregnant lactating HIV positive CNS involvement by lymphoma other malignancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Doug Stewart

Role: PRINCIPAL_INVESTIGATOR

Alberta Cancer Board - TBCC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tom Baker Cancer Centre

Calgary, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Stewart DA, Duan Q, Carlson L, Russell JA, Bahlis NJ, Duggan P, Hasegawa W, Voralia M. A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):475-82. doi: 10.1016/j.clml.2011.06.012. Epub 2011 Aug 10.

Reference Type DERIVED

PMID: 21831743 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15841

Identifier Type: -

Identifier Source: secondary_id

147